Fate Therapeutics (FATE) Cash from Investing Activities (2012 - 2026)

Fate Therapeutics' Cash from Investing Activities history runs 15 years deep, the most recent figure standing at $23.6 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 44.73% year-over-year to $23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92.1 million (up 145.04% YoY) and the FY2025 annual result came in at $111.2 million, up 809.85% from the prior year.
• Cash from Investing Activities was $23.6 million for Q1 2026 at Fate Therapeutics, down from $27.6 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $80.4 million in Q3 2022 and bottomed at -$53.4 million in Q2 2024.
• A 5-year average of $25.1 million and a median of $24.8 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 3036.37% — and 2024, when it plunged 260.92%.
• Fate Therapeutics' Cash from Investing Activities stood at $53.1 million in 2022, then decreased by 14.61% to $45.4 million in 2023, then slumped by 49.69% to $22.8 million in 2024, then gained by 21.1% to $27.6 million in 2025, then slipped by 14.63% to $23.6 million in 2026.
• Business Quant data shows FATE's Cash from Investing Activities at $23.6 million in Q1 2026, $27.6 million in Q4 2025, and $21.3 million in Q3 2025.